Day: February 28, 2023

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) — American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB. V), today announced its financial results for the three months and year ended December 31, 2022. All amounts presented in this news release are in United States dollars (“U.S. dollars”) unless otherwise indicated. “We continued to achieve strong revenue performance from our select service hotel portfolio in Q4.” commented Jonathan Korol, CEO. “Despite macroeconomic challenges, we have not seen any weakness in corporate, group or leisure demand channels. Consistent with prior periods of high inflation, we are experiencing rate growth that exceeds inflation with an annual increase in average daily rate (“ADR”) (1) of 12.7%. However, broad cost pressures...

Company continues to see strong growth with a 4.4x increase in Energy Block shipments vs. FY 2021. EDISON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced financial results for the fourth quarter and full year ended December 31, 2022. Full Year 2022 HighlightsRevenue of $17.9 million compared to $4.6 million in 2021, representing approximately 4x revenue growth year-over-year. Increased current opportunity pipeline by 83% year-over-year to $7.5 billion, which includes 4GWh in LOIs. Costs of Goods Sold of $153.3 million, driven by a 44% reduction in unit product cost year-over-year. Booked orders increased 2.5x to $338.6 million...

TORONTO, Feb. 28, 2023 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the fourth quarter and year ended December 31, 2022. David Clare, President and CEO of Trisura, stated, “Despite strong adjusted earnings and operating performance, results in the quarter were impacted by a one-time $64.4 million write down (tax effected) of reinsurance recoverables in our US fronting business, resulting in a consolidated quarterly loss of $40.3 million or ($0.86) per share. Adjusted quarterly net income which provides a normalized view of performance, was $23.7 million or $0.51 per share. Notwithstanding the impact of this write down, Trisura is a larger, more diversified entity than at any stage in our history. We believe firmly that...

MANAGEMENT REPORT Consolidated net sales for Q4 2022 were € 2.03 million (down from € 2.34 million in Q4 2021). The main business area of production and wholesale of fibreboard recorded sales in Q4 2022 of € 2.02 million, 12% down from sales in Q4 2021. The remaining business area is real estate management of the property owned in Suur-Jõe Street in Pärnu, who recorded sales of € 11 thousand in Q4 2022 (Q4 2021: 36 thousand). Consolidated sales for the full year 2022 was € 11.07 million, which is an increase of 10% compared to 2021 full year sales of € 10.10 million. The reason for such sales increase is due to increased sales of fibreboards in our key markets such as Finland, Denmark, Estonia and Latvia. However, the Group’s gross margin fell from 33% for full year 2021 to becoming 23% for full year 2022, the main reasons being the increased...

Reports $1.43 billion in total revenue for 2022, up 23% year-over-year Beats high end of fourth quarter and full-year guidance on revenue, adjusted gross profit and adjusted EBITDA Demonstrates replicability of the company’s clinical management capabilities outside its core markets through its Care Anywhere clinical model and proprietary AVA® data platform, reporting nearly 40% fewer hospitalizations than traditional Medicare in California and each new marketORANGE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Alignment Healthcare USA, LLC (NASDAQ: ALHC), please note that in the “Outlook for First Quarter and Fiscal Year 2023” section, the table header read “Twelve Months Ending March 31, 2023” but should have read “Twelve Months Ending...

OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021. The revenues for fiscal 2022 consisted of $29.8 million in processing and storage fee revenue, $104,000 in product revenue and $462,000 in public banking revenue compared to $28.4 million in processing and storage fee revenue, $111,000 in product revenue and $376,000 in public banking revenue for fiscal 2021. Net Income The Company reported net income of $2.8 million in fiscal 2022 or $0.33 per basic and diluted share, compared to net income...

TORONTO, Feb. 28, 2023 (GLOBE NEWSWIRE) — Field Trip Health & Wellness Ltd. (TSXV: FTHW) (OTCQB: FTHWF) (the “Company” or “Field Trip”), a global leader in the delivery of psychedelic therapies, provided a business update today and reported its fiscal third quarter 2023 results for the three and nine month periods ended December 31, 2022. All results are reported in accordance with International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. In December 2022, the Company formed an independent committee (the “IC”) of the board of directors of the Company (the “Board”) to assess strategic options for the Company. The formation of the IC was in response to, among other things, current unfavourable capital market conditions, which have presented...

HOUSTON, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Specialty” or the “Company”) today reported fourth quarter 2022 net income of $20.4 million, or $0.63 per diluted share, compared to $1.3 million, or $0.04 per diluted share, for the same 2021 period. Adjusted operating income(1) for the fourth quarter of 2022 was $11.6 million, or $0.36 per diluted share, compared to $7.6 million, or $0.23 per diluted share, for the same 2021 period. Highlights for the quarter included:Gross written premiums increased 18.1%, while continuing business grew 21.4% compared to the fourth quarter of 2021. Combined ratio of 92.4% compared to 106.8% for the fourth quarter 2021. Adjusted combined ratio(1) of 92.8% compared to 94.8% for the fourth quarter 2021. Net investment income increased...

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 – MCLA-129 clinical update planned for second half of 2023  – Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into second half 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update. “We are making significant progress across our clinical...